Management of Heart Failure

David William Baker, Marvin A. Konstam, Michael Bottorff, Bertram Pitt

ResearchPosted on rand.org 1994Published In: JAMA, The Journal of the American Medical Association, v. 272, no. 17, Nov. 2, 1994, p. 1361-1366

Deals with pharmacological treatment of congestive heart failure (CHF). It concludes that angiotensin-converting-enzyme (ACE) inhibitors should be given to all patients who have experienced heart failure unless specific contraindications exist. Diuretics should be used judiciously early in treatment to prevent excess diuresis. Digoxin has not been shown to affect the natural history of heart failure, and isosorbide dinitrate and hydralazine hydrochloride should be tried in patients who cannot tolerate ACE inhibitors or who have refractory symptoms.

Read More

Topics

Document Details

  • Copyright: American Medical Association
  • Availability: Non-RAND
  • Year: 1994
  • Pages: 6
  • Document Number: EP-199411-07

This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.